{"filing":{"accession_number":"0001193125-26-279428","cik":"0001817713","ticker":"JANX","company_name":"Janux Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"janx-20260623.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817713/000119312526279428/janx-20260623.htm"},"events":[{"id":13152,"run_id":11672,"accession_number":"0001193125-26-279428","anchor_item_number":"8.01","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"William Go, M.D., Ph.D., Chief Medical Officer of Janux Therapeutics, departed on June 23, 2026, under a termination without \"Cause\" under the Company's Change in Control and Severance Benefit Plan. The disclosure centers on the departure of a named executive officer and the triggering of severance benefits, making this a clear executive departure event. The company's statement that the transition does not affect development strategy or clinical timelines is a standard mitigation statement but does not change the materiality of the CMO's departure.","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10218,"accession_number":"0001193125-26-279428","item_number":"8.01","item_title":"Other Events.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"William Go, M.D., Ph.D., Chief Medical Officer of Janux Therapeutics, departed on June 23, 2026, under a termination without \"Cause\" under the Company's Change in Control and Severance Benefit Plan. The disclosure centers on the departure of a named executive officer and the triggering of severance benefits, making this a clear executive departure event. The company's statement that the transition does not affect development strategy or clinical timelines is a standard mitigation statement but does not change the materiality of the CMO's departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:08:38.416213+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10218,"accession_number":"0001193125-26-279428","item_number":"8.01","item_title":"Other Events.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"William Go, M.D., Ph.D., Chief Medical Officer of Janux Therapeutics, departed on June 23, 2026, under a termination without \"Cause\" under the Company's Change in Control and Severance Benefit Plan. The disclosure centers on the departure of a named executive officer and the triggering of severance benefits, making this a clear executive departure event. The company's statement that the transition does not affect development strategy or clinical timelines is a standard mitigation statement but does not change the materiality of the CMO's departure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T20:08:38.416213+00:00","company_name":"Janux Therapeutics, Inc.","ticker":"JANX","filing_date":"2026-06-23"}]}